These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15768380)

  • 21. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
    Rodriguez-Galindo C; Crews KR; Stewart CF; Furman W; Panetta JC; Daw NC; Cain A; Tan M; Houghton PH; Santana VM
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):15-24. PubMed ID: 16001174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
    Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
    Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.
    Chang TC; Shiah HS; Yang CH; Yeh KH; Cheng AL; Shen BN; Wang YW; Yeh CG; Chiang NJ; Chang JY; Chen LT
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):579-86. PubMed ID: 25577133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
    Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study.
    Aquino VM; Weitman SD; Winick NJ; Blaney S; Furman WL; Kepner JL; Bonate P; Krailo M; Qu W; Bernstein M
    J Clin Oncol; 2004 Apr; 22(8):1413-9. PubMed ID: 15084615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
    Garrison MA; Hammond LA; Geyer CE; Schwartz G; Tolcher AW; Smetzer L; Figueroa JA; Ducharme M; Coyle J; Takimoto CH; De Jager RL; Rowinsky EK
    Clin Cancer Res; 2003 Jul; 9(7):2527-37. PubMed ID: 12855627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
    Trippett TM; Herzog C; Whitlock JA; Wolff J; Kuttesch J; Bagatell R; Hunger SP; Boklan J; Smith AA; Arceci RJ; Katzenstein HM; Harbison C; Zhou X; Lu H; Langer C; Weber M; Gore L
    J Clin Oncol; 2009 Oct; 27(30):5102-8. PubMed ID: 19770383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
    Mugishima H; Matsunaga T; Yagi K; Asami K; Mimaya J; Suita S; Kishimoto T; Sawada T; Tsuchida Y; Kaneko M
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):94-100. PubMed ID: 11990713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
    Moreno L; Casanova M; Chisholm JC; Berlanga P; Chastagner PB; Baruchel S; Amoroso L; Gallego Melcón S; Gerber NU; Bisogno G; Fagioli F; Geoerger B; Glade Bender JL; Aerts I; Bergeron C; Hingorani P; Elias I; Simcock M; Ferrara S; Le Bruchec Y; Slepetis R; Chen N; Vassal G
    Eur J Cancer; 2018 Sep; 100():27-34. PubMed ID: 29936064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.
    Ford HE; Cunningham D; Ross PJ; Rao S; Aherne GW; Benepal TS; Price T; Massey A; Vernillet L; Gruia G
    Br J Cancer; 2000 Jul; 83(2):146-52. PubMed ID: 10901362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
    Murren JR; Peccerillo K; DiStasio SA; Li X; Leffert JJ; Pizzorno G; Burtness BA; McKeon A; Cheng Y
    Cancer Chemother Pharmacol; 2000; 46(1):43-50. PubMed ID: 10912577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
    Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
    Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
    Royce ME; Hoff PM; Dumas P; Lassere Y; Lee JJ; Coyle J; Ducharme MP; De Jager R; Pazdur R
    J Clin Oncol; 2001 Mar; 19(5):1493-500. PubMed ID: 11230496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
    Tubergen DG; Stewart CF; Pratt CB; Zamboni WC; Winick N; Santana VM; Dryer ZA; Kurtzberg J; Bell B; Grier H; Vietti TJ
    J Pediatr Hematol Oncol; 1996 Nov; 18(4):352-61. PubMed ID: 8888741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
    Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
    Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.
    Kuppens IE; Dansin E; Boot H; Feger C; Assadourian S; Bonneterre ME; Beijnen JH; Schellens JH; Bonneterre J
    Clin Cancer Res; 2006 Jun; 12(12):3774-81. PubMed ID: 16778105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
    Vassal G; Couanet D; Stockdale E; Geoffray A; Geoerger B; Orbach D; Pichon F; Gentet JC; Picton S; Bergeron C; Cisar L; Assadourian S; Morland B; ;
    J Clin Oncol; 2007 Feb; 25(4):356-61. PubMed ID: 17264330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
    Takimoto CH; Morrison G; Harold N; Quinn M; Monahan BP; Band RA; Cottrell J; Guemei A; Llorens V; Hehman H; Ismail AS; Flemming D; Gosky DM; Hirota H; Berger SJ; Berger NA; Chen AP; Shapiro JD; Arbuck SG; Wright J; Hamilton JM; Allegra CJ; Grem JL
    J Clin Oncol; 2000 Feb; 18(3):659-67. PubMed ID: 10653882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.
    Garcia AA; Pujari M; Jeffers S; Iqbal S; Lenz HJ; Beringer P; Louie S
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):75-82. PubMed ID: 15809878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.